T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

Saskia J A M Santegoets, Anita G M Stam, Sinéad M. Lougheed, Helen Gall, Petra E T Scholten, Martine Reijm, Karin Jooss, Natalie Sacks, Kristen Hege, Israel Lowy, Jean Marie Cuillerot, B. Mary E Von Blomberg, Rik J. Scheper, Alfons J M Van Den Eertwegh, Winald R. Gerritsen, Tanja D. De Gruijl

Research output: Contribution to journalArticle

Abstract

Immune checkpoint blockade enhances antitumor responses, but can also lead to severe immune-related adverse events (IRAE). To avoid unnecessary exposure to these potentially hazardous agents, it is important to identify biomarkers that correlate with clinical activity and can be used to select patients that will benefit from immune checkpoint blockade. To understand the consequences of CTLA-4 blockade and identify biomarkers for clinical efficacy and/or survival, an exploratory T cell monitoring study was performed in a phase I/II dose escalation/expansion trial (n = 28) of combined Prostate GVAX/ipilimumab immunotherapy. Phenotypic T cell monitoring in peripheral blood before and after Prostate GVAX/ipilimumab treatment revealed striking differences between patients who benefited from therapy and patients that did not. Treatment-induced rises in absolute lymphocyte counts, CD4+ T cell differentiation, and CD4+ and CD8+ T cell activation were all associated with clinical benefit. Moreover, significantly prolonged overall survival (OS) was observed for patients with high pre-treatment frequencies of CD4 +CTLA-4+, CD4+PD-1+, or differentiated (i.e., non-naive) CD8+ T cells or low pre-treatment frequencies of differentiated CD4+ or regulatory T cells. Unsupervised clustering of these immune biomarkers revealed cancer-related expression of CTLA-4+ in CD4+ T cells to be a dominant predictor for survival after Prostate GVAX/ipilimumab therapy and to thus provide a putative and much-needed biomarker for patient selection prior to therapeutic CTLA4 blockade.

Original languageEnglish (US)
Pages (from-to)245-256
Number of pages12
JournalCancer Immunology Immunotherapy
Volume62
Issue number2
DOIs
StatePublished - Feb 2013
Externally publishedYes

Fingerprint

Prostate
T-Lymphocytes
Survival
Biomarkers
Therapeutics
Regulatory T-Lymphocytes
CD4 Lymphocyte Count
Tumor Biomarkers
ipilimumab
Immunotherapy
Patient Selection
Cluster Analysis
Cell Differentiation

Keywords

  • Biomarker
  • Ipilimumab
  • Patient selection
  • Prostate GVAX
  • Survival prediction

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Immunology
  • Immunology and Allergy

Cite this

Santegoets, S. J. A. M., Stam, A. G. M., Lougheed, S. M., Gall, H., Scholten, P. E. T., Reijm, M., ... De Gruijl, T. D. (2013). T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment. Cancer Immunology Immunotherapy, 62(2), 245-256. https://doi.org/10.1007/s00262-012-1330-5

T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment. / Santegoets, Saskia J A M; Stam, Anita G M; Lougheed, Sinéad M.; Gall, Helen; Scholten, Petra E T; Reijm, Martine; Jooss, Karin; Sacks, Natalie; Hege, Kristen; Lowy, Israel; Cuillerot, Jean Marie; Von Blomberg, B. Mary E; Scheper, Rik J.; Van Den Eertwegh, Alfons J M; Gerritsen, Winald R.; De Gruijl, Tanja D.

In: Cancer Immunology Immunotherapy, Vol. 62, No. 2, 02.2013, p. 245-256.

Research output: Contribution to journalArticle

Santegoets, SJAM, Stam, AGM, Lougheed, SM, Gall, H, Scholten, PET, Reijm, M, Jooss, K, Sacks, N, Hege, K, Lowy, I, Cuillerot, JM, Von Blomberg, BME, Scheper, RJ, Van Den Eertwegh, AJM, Gerritsen, WR & De Gruijl, TD 2013, 'T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment', Cancer Immunology Immunotherapy, vol. 62, no. 2, pp. 245-256. https://doi.org/10.1007/s00262-012-1330-5
Santegoets, Saskia J A M ; Stam, Anita G M ; Lougheed, Sinéad M. ; Gall, Helen ; Scholten, Petra E T ; Reijm, Martine ; Jooss, Karin ; Sacks, Natalie ; Hege, Kristen ; Lowy, Israel ; Cuillerot, Jean Marie ; Von Blomberg, B. Mary E ; Scheper, Rik J. ; Van Den Eertwegh, Alfons J M ; Gerritsen, Winald R. ; De Gruijl, Tanja D. / T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment. In: Cancer Immunology Immunotherapy. 2013 ; Vol. 62, No. 2. pp. 245-256.
@article{a4e40162a0de4490b5afd19d2355331b,
title = "T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment",
abstract = "Immune checkpoint blockade enhances antitumor responses, but can also lead to severe immune-related adverse events (IRAE). To avoid unnecessary exposure to these potentially hazardous agents, it is important to identify biomarkers that correlate with clinical activity and can be used to select patients that will benefit from immune checkpoint blockade. To understand the consequences of CTLA-4 blockade and identify biomarkers for clinical efficacy and/or survival, an exploratory T cell monitoring study was performed in a phase I/II dose escalation/expansion trial (n = 28) of combined Prostate GVAX/ipilimumab immunotherapy. Phenotypic T cell monitoring in peripheral blood before and after Prostate GVAX/ipilimumab treatment revealed striking differences between patients who benefited from therapy and patients that did not. Treatment-induced rises in absolute lymphocyte counts, CD4+ T cell differentiation, and CD4+ and CD8+ T cell activation were all associated with clinical benefit. Moreover, significantly prolonged overall survival (OS) was observed for patients with high pre-treatment frequencies of CD4 +CTLA-4+, CD4+PD-1+, or differentiated (i.e., non-naive) CD8+ T cells or low pre-treatment frequencies of differentiated CD4+ or regulatory T cells. Unsupervised clustering of these immune biomarkers revealed cancer-related expression of CTLA-4+ in CD4+ T cells to be a dominant predictor for survival after Prostate GVAX/ipilimumab therapy and to thus provide a putative and much-needed biomarker for patient selection prior to therapeutic CTLA4 blockade.",
keywords = "Biomarker, Ipilimumab, Patient selection, Prostate GVAX, Survival prediction",
author = "Santegoets, {Saskia J A M} and Stam, {Anita G M} and Lougheed, {Sin{\'e}ad M.} and Helen Gall and Scholten, {Petra E T} and Martine Reijm and Karin Jooss and Natalie Sacks and Kristen Hege and Israel Lowy and Cuillerot, {Jean Marie} and {Von Blomberg}, {B. Mary E} and Scheper, {Rik J.} and {Van Den Eertwegh}, {Alfons J M} and Gerritsen, {Winald R.} and {De Gruijl}, {Tanja D.}",
year = "2013",
month = "2",
doi = "10.1007/s00262-012-1330-5",
language = "English (US)",
volume = "62",
pages = "245--256",
journal = "Cancer Immunology and Immunotherapy",
issn = "0340-7004",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "2",

}

TY - JOUR

T1 - T cell profiling reveals high CD4+CTLA-4+ T cell frequency as dominant predictor for survival after Prostate GVAX/ipilimumab treatment

AU - Santegoets, Saskia J A M

AU - Stam, Anita G M

AU - Lougheed, Sinéad M.

AU - Gall, Helen

AU - Scholten, Petra E T

AU - Reijm, Martine

AU - Jooss, Karin

AU - Sacks, Natalie

AU - Hege, Kristen

AU - Lowy, Israel

AU - Cuillerot, Jean Marie

AU - Von Blomberg, B. Mary E

AU - Scheper, Rik J.

AU - Van Den Eertwegh, Alfons J M

AU - Gerritsen, Winald R.

AU - De Gruijl, Tanja D.

PY - 2013/2

Y1 - 2013/2

N2 - Immune checkpoint blockade enhances antitumor responses, but can also lead to severe immune-related adverse events (IRAE). To avoid unnecessary exposure to these potentially hazardous agents, it is important to identify biomarkers that correlate with clinical activity and can be used to select patients that will benefit from immune checkpoint blockade. To understand the consequences of CTLA-4 blockade and identify biomarkers for clinical efficacy and/or survival, an exploratory T cell monitoring study was performed in a phase I/II dose escalation/expansion trial (n = 28) of combined Prostate GVAX/ipilimumab immunotherapy. Phenotypic T cell monitoring in peripheral blood before and after Prostate GVAX/ipilimumab treatment revealed striking differences between patients who benefited from therapy and patients that did not. Treatment-induced rises in absolute lymphocyte counts, CD4+ T cell differentiation, and CD4+ and CD8+ T cell activation were all associated with clinical benefit. Moreover, significantly prolonged overall survival (OS) was observed for patients with high pre-treatment frequencies of CD4 +CTLA-4+, CD4+PD-1+, or differentiated (i.e., non-naive) CD8+ T cells or low pre-treatment frequencies of differentiated CD4+ or regulatory T cells. Unsupervised clustering of these immune biomarkers revealed cancer-related expression of CTLA-4+ in CD4+ T cells to be a dominant predictor for survival after Prostate GVAX/ipilimumab therapy and to thus provide a putative and much-needed biomarker for patient selection prior to therapeutic CTLA4 blockade.

AB - Immune checkpoint blockade enhances antitumor responses, but can also lead to severe immune-related adverse events (IRAE). To avoid unnecessary exposure to these potentially hazardous agents, it is important to identify biomarkers that correlate with clinical activity and can be used to select patients that will benefit from immune checkpoint blockade. To understand the consequences of CTLA-4 blockade and identify biomarkers for clinical efficacy and/or survival, an exploratory T cell monitoring study was performed in a phase I/II dose escalation/expansion trial (n = 28) of combined Prostate GVAX/ipilimumab immunotherapy. Phenotypic T cell monitoring in peripheral blood before and after Prostate GVAX/ipilimumab treatment revealed striking differences between patients who benefited from therapy and patients that did not. Treatment-induced rises in absolute lymphocyte counts, CD4+ T cell differentiation, and CD4+ and CD8+ T cell activation were all associated with clinical benefit. Moreover, significantly prolonged overall survival (OS) was observed for patients with high pre-treatment frequencies of CD4 +CTLA-4+, CD4+PD-1+, or differentiated (i.e., non-naive) CD8+ T cells or low pre-treatment frequencies of differentiated CD4+ or regulatory T cells. Unsupervised clustering of these immune biomarkers revealed cancer-related expression of CTLA-4+ in CD4+ T cells to be a dominant predictor for survival after Prostate GVAX/ipilimumab therapy and to thus provide a putative and much-needed biomarker for patient selection prior to therapeutic CTLA4 blockade.

KW - Biomarker

KW - Ipilimumab

KW - Patient selection

KW - Prostate GVAX

KW - Survival prediction

UR - http://www.scopus.com/inward/record.url?scp=84874116175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84874116175&partnerID=8YFLogxK

U2 - 10.1007/s00262-012-1330-5

DO - 10.1007/s00262-012-1330-5

M3 - Article

C2 - 22878899

AN - SCOPUS:84874116175

VL - 62

SP - 245

EP - 256

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 2

ER -